Muted Q2 But Biocon Confident Of Insulin Glargine’s Onward US March
Ogivri Trastuzumab Biosimilar “held ground” in the US with a 6% share
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.
